414 results about "Influenza a" patented technology

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

Provided herein are isolated polynucleotides encoding a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. Also provided herein are isolated polynucleotides encoding alphaviral non-structural proteins nsp1, nsp2, nsp3, and nsp4 and polypeptides comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. The antigen may be influenza. Polynucleotides, such as RNAs, can be used as vaccines against influenza infection.

A bioenergy generator to increase the life force of a biological system is provided. The bioenergy generator includes fine pieces of natural stone, fine pieces of natural sand, fine pieces of metal, water and a supporting material operable to hold the natural sand, the natural stone, the metal, and the water together. Uses of the bioenergy generator are also provided, in particular, to treat long-COVID and influenza.

The invention belongs to the technical field of virus detection, and discloses a digital PCR (Polymerase Chain Reaction) kit for simultaneously detecting African horse pestivirus, West Nile virus and equine influenza H3N8, and the kit comprises primers and probes as shown in SEQ ID NO.1-SEQ ID NO.21. The invention also discloses a kit for simultaneously detecting African horse pestivirus, West Nile virus and equine influenza H3N8. According to the invention, after a single system of an African horse pestivirus VP7 gene, an African horse pestivirus-NS2 gene, a west nile virus-NS5 gene, a west nile virus-NS2a gene, an equine influenza H3N8-HA gene and an equine influenza H3N8-NA gene is tested, a seven-fold digital PCR (Polymerase Chain Reaction) system containing an internal standard is established; through tests of indexes such as linearity, specificity, minimum detection limit, repeatability, comparison of a single digital PCR system and a multiple digital PCR system, the currently developed digital PCR multiple detection kit completely meets development requirements and is high in specificity and sensitivity, and the minimum detection limit of the digital PCR multiple detection kit can reach 10 Copies / mu L or below.

The invention provides an influenza prevalence trend prediction and early warning method, which comprises the following steps of S1, collecting multi-source data consisting of monitored epidemic situation data, monitored event data and meteorological data, analyzing influenza epidemiological characteristics, and screening influenza prediction and early warning indexes; s2, analyzing the influenza epidemic situation, and predicting the influenza epidemic trend; and S3, analyzing the flu prevalence signal, and performing early warning on the flu prevalence abnormal signal. The method has the beneficial effects that the prediction and early warning model of the influenza epidemiology trend is established by analyzing the influenza epidemiology characteristics, and reference is provided for the public and related health departments to deal with the influenza in time.

The invention belongs to the field of biological medicine industry, and discloses a blood marker for assisting in diagnosing influenza. The inventor verifies that the LRG1 is a peripheral blood marker of influenza for the first time and can be used for auxiliary diagnosis of influenza and increase of the detection rate of influenza virus by being matched with multiple times of detection of influenza virus. A test result shows that the peripheral blood LRG1 content 5ng / ml is a CUTOFF value, 46 patients and 4 false negative patients are successfully detected for 50 influenza patients, and the sensitivity is 92%; the number of normal persons is 60, the number of the normal persons is 12, and the specificity is 80%. After influenza treatment, LRG1 and Plt are obviously reduced compared with those before influenza treatment; 0.001, which is equivalent to the level of normal people, Pgt; and 0.05%.

The present application provides chimeric proteins comprising an antibody moiety that specifically binds to a component of an influenza virus or a variant thereof, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating an infection caused by an influenza virus or a variant thereof in an individual.

The invention provides a kit and a method for simultaneously detecting 11 pathogens of a urogenital system and application, and belongs to the field of molecular biology. The primer group is used for detecting urogenital tract pathogens, and the urogenital tract pathogens comprise ureaplasma urealyticum (UU), chlamydia trachomatis (CT), mycoplasma genitalium (MG), ureaplasma parvum (UP), mycoplasma hominis (MH), adenovirus (ADV), trichomonas vaginalis (TV), herpes simplex virus type I (HSV-I), herpes simplex virus type II (HSV-II), haemophilus influenzae (HI) and neisseria gonorrhoeae (NG). The primer group is used for multi-joint detection of non-gonococcal urethritis related pathogens, has high specificity and sensitivity, is adaptive to non-invasive urine specimens, and supports home self-sampling. The kit is used for clinical diagnosis and can quickly judge pathogen types. Precise medication is performed based on a detection result, the healing time of a patient is shortened, the burden of a doctor is relieved, and meanwhile the pathogen transmission risk is reduced.

The invention discloses a freeze-drying protection system for an influenza live attenuated vaccine. The freeze-drying protection system is composed of a buffer solution and auxiliary materials. The freeze-dried powder is safe and effective, has a relatively good protection effect on an influenza attenuated strain, is relatively low in virus loss before and after freeze-drying, and has good storage stability.

The present invention uses ex vivo human airway cultures to assess the human transmissibility and replication competence of influenza and coronavirus strains. By comparing pandemic influenza A subtype H1N1 and highly pathogenic avian influenza H5N1 as reference strains, the transmissibility risk of various viruses was evaluated and categorized. Additionally, an in vitro model evaluated virus-induced impairment of alveolar fluid clearance (AFC) as an indicator of disease severity. The study revealed correlations between bronchus viral replication, human transmission, AFC impairment, and clinical disease severity across different influenza and coronavirus strains.

Provided are an anti-neuraminidase human monoclonal antibody obtained by means of multiple rounds of in-vitro screening and recombinant modification, and the use thereof in the preparation of a product for preventing, detecting, or treating influenza viruses. The provided monoclonal antibody exhibits significant neuraminidase inhibitory activity and broad-spectrum binding capacity to influenza virus antigens, shows excellent preventive and therapeutic effects against multiple seasonal influenza viruses, provides a new technical option for resisting influenza infection, and has great application value.

The invention discloses a VZV antigen variant, nucleic acid, a pharmaceutical composition and application of the VZV antigen variant. The VZV antigen variant has a Y582G difference compared with an amino acid sequence as shown in SEQ ID NO: 1; and / or the VZV antigen variant has the deletion of 561 to 623 sites, 569 to 623 sites or 574 to 623 sites compared with the amino acid sequence as shown in SEQ ID NO: 1, and / or the VZV antigen variant has the deletion of 561 to 623 sites, 569 to 623 sites or 574 to 623 sites; and / or the VZV antigen variant is a modification having a protein transmembrane region and an intracellular region compared with the amino acid sequence as shown in SEQ ID NO: 1, and the modification of the protein transmembrane region and the intracellular region is that the transmembrane region and the intracellular region of the original VZV antigen are replaced by a transmembrane region of SARS-CoV-2Spike protein or a transmembrane region of influenza H protein. Compared with the VZV antigen in the prior art, the VZV antigen variant has stronger immunogenicity, can obtain higher binding antibody titer, and has higher protective efficacy.

The invention belongs to the technical field of drug synthesis, and particularly relates to an adamantane derivative as well as a synthesis method and application thereof. The adamantane derivative comprises an intermediate structural formula I, an intermediate structural formula II and an intermediate structural formula III, and the structural general formula is as follows: Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the adamantane derivative provided by the invention, an adamantane structure is combined with part of groups of OAB-14, and a parent nucleus structure is changed, so that the drug activity is improved. The invention also provides a synthesis method of the compound, the obtained compound is screened through cell viability research, and the compound has a potential synergistic effect in the aspects of preventing influenza and treating Alzheimer's disease.

The invention provides an anti-influenza A virus nano antibody and application thereof, the nano antibody comprises a heavy chain variable region, the heavy chain variable region comprises CDR1, CDR2 and CDR3, and the CDR3 of the heavy chain variable region is selected from an amino acid sequence as shown in SEQ ID NO: 8 or SEQ ID NO: 16. The anti-influenza A virus nano antibody can be combined with various influenza A viruses, including subtype influenza viruses such as H1N1, H2N2, H3N2 and H7N9, has strong broad spectrum, has different binding epitopes of the two nano antibodies, and can be applied to double antibody sandwich method detection, enzyme-linked immunosorbent assay and colloidal gold detection. According to the invention, multivalent transformation is also carried out on the nano antibody to obtain a dodecavalent hexamer cyclic structure nano antibody, so that the application scene of the anti-influenza A virus nano antibody can be further extended.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to tubeimoside B liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving phospholipid, cholesterol and PEGylated phospholipid in an organic solvent to form a mixed solution, and then evaporating the mixed solution to form a film; and hydrating the film by using an aqueous solution of tubeimoside B to finally prepare the tubeimoside B liposome. Compared with free tubeimoside B, the lipidosome has the advantages that the hemolysis percentage is obviously reduced, and antigen-specific humoral immune response and / or cellular immune response can be effectively enhanced when the lipidosome is used as a vaccine adjuvant. In an H1N1 influenza mouse model, the lipidosome combined antigen shows an excellent protection effect, which is shown in that the mouse weight fluctuation is relatively small and the lung virus load is remarkably reduced. The invention provides important theoretical basis and practical examples for developing low-toxicity and high-efficiency plant-derived vaccine adjuvants, and has a wide application prospect.

The invention relates to the technical field of biology, and particularly discloses a kit for detecting haemophilus influenzae based on PCR (Polymerase Chain Reaction) / RAA-CRISPR-Cas13a. The invention discloses a kit for detecting a haemophilus influenzae gene on the basis of PCR (Polymerase Chain Reaction) / RAA-CRISPR-Cas13a. The kit comprises a primer pair for specifically amplifying haemophilus influenzae genes and crRNA, the sequence of the crRNA is composed of an anchoring sequence used for being combined with Cas13a protein and a guide sequence of a target sequence of the haemophilus influenzae genes, and the guide sequence is shown as the 39-66th site of SEQ ID No.28. The invention constructs a method for detecting haemophilus influenzae genes by combining a PCR or RAA technology with a CRISPR-Cas13a technology, the method is simple, convenient and rapid, has higher sensitivity and specificity, can reach a single copy level in sensitivity, and can be used for clinically and rapidly identifying whether the haemophilus influenzae is infected or not.

Provided is an isolated mRNA molecule, which contains a nucleotide sequence encoding a chimeric immunogenic polypeptide, wherein the chimeric immunogenic polypeptide contains an immunogenic fragment of hemagglutinin (HA) of influenza A H5N1, an immunogenic fragment of hemagglutinin (HA) of influenza A H1N1, and an immunogenic fragment of hemagglutinin (HA) of influenza B Victoria, which are linked to each other. Further provided are a composition and vaccine containing the mRNA, a fusion protein encoded thereby, and a method using same for inducing an immune response to influenza virus in a subject.

Livestock animals and progeny thereof comprising at least one modified chromosomal sequence that reduces expression or activity of a Transmembrane Serine Protease 2 (TMPRSS2) protein and / or a Transmembrane Serine Protease 4 (TMPRSS4) protein are provided. Livestock animal cells that contain such edited chromosomal sequences are also provided. The livestock animals, progeny, and cells have increased resistance to influenza viruses and coronaviruses. Methods for producing influenza resistant and porcine epidemic diarrhea resistant livestock animals are also provided.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

The invention provides a traditional Chinese medicine composition for treating influenza. The traditional Chinese medicine composition is prepared from the following medicinal components in parts by weight: 8-12 parts of radix puerariae, 1-5 parts of roasted herba ephedrae, 18-22 parts of gypsum, 3-7 parts of semen armeniacae amarae, 4-8 parts of radix bupleuri, 4-8 parts of notopterygium root, 4-8 parts of folium isatidis, 4-8 parts of medicated leaven and 1-5 parts of liquorice. The flu is exterior cold and interior heat syndrome. The traditional Chinese medicine composition is capable of alleviating drug properties, preventing excessive warm-dryness of ephedra and preventing cold-cold stomach injury of gypsum. The medicines are used for supplementing the deficiency of monarch and ministerial drugs, so that the effects of relieving exterior syndrome, dispelling cold and clearing internal heat are enhanced. According to the formula, all the medicines are combined to achieve the effects of relieving exterior syndrome, dispelling cold and clearing internal heat, so that evil is removed, exterior syndrome is eliminated, qi and blood are smooth, and the whole function is achieved. Generally, the prescription is rigorous, the compatibility is proper, and the traditional Chinese medicine is clinically effective.

This article provides a combination of compounds that can inhibit influenza virus replication, reduce influenza virus load, and / or treat influenza.

The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses like SARS-COV-2, influenza and HIV / AIDS, when administered via pulmonary and dermal route. While the different forms of cyclodextrin prevent the entry of coated virus into host cells by extracting and sequestering cholesterol molecules at the virus coat and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation, enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. Hence cyclodextrine, and quercetin plus zinc, either in combination or in tandem order of administration, serves both as prophylactic and therapeutic.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

Described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 49. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 81 to 143. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137515 to 137675. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137682 to 137830.

The invention discloses a compound of formula I; specifically, the invention relates to a compound as shown in a formula I or a stereoisomer, a tautomer, an isotope derivative and pharmaceutically acceptable salt thereof, and application of the compound as shown in the formula I and a composition of the compound as an anti-influenza virus drug. # imgabs0 #

The present invention relates to an immunogenic composition comprising two or more polypeptides. The invention also provides nucleic acid molecules and vectors encoding the polypeptides, and methods of using the compositions, nucleic acid molecules and vectors for the prevention or treatment of influenza.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

The invention discloses a large-scale closed public place aerosol virus enrichment monitoring system based on an STM32 main control platform, which combines an air sampler and a microfluidic analysis technology, adopts a temperature and humidity real-time monitoring module, optimizes an air sampling and virus enrichment process, and realizes that an integrated microfluidic analysis unit completes rapid determination of virus concentration. According to the system, virus concentration detection is carried out on an enriched sample by utilizing a double-antibody sandwich enzyme-linked immunoassay technology, and the virus concentration is determined through absorbance measurement. Experiments show that the detection error of the system is lower than 5%, and virus monitoring which is quick in response, convenient to operate and low in cost can be achieved. The system is suitable for monitoring viruses such as influenza, new coronavirus and norovirus in large closed public places, and provides efficient technical support for public health safety.